Symphony Limited — Investor Meet, 22-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Symphony's Q4FY26/FY26 results saw consolidated revenue at ₹1,131 Cr (down 28% YoY) with a negative PAT of ₹141 Cr, primarily due to a ₹348 Cr write-off for its Australia business. Management confirmed no further capital will be allocated to Australia, shifting to a distribution model. The US business, now a direct subsidiary, shows strong momentum. GSK China is profitable and almost debt-free to Symphony India. India operations faced early summer challenges with inventory overhang but expect better sales from May. Beyond India Summer Products (BISP) contribute 49% of revenue. Gross margins are stable, with cost increases to be passed on from July. The company emphasizes capital efficiency post-restructuring.